Wikipedia -WSS

Wikipedia

author：comprehensive 2025-08-28 06:24:05 - browse：83597

Stock exchange — Drew Angerer/Getty Images

Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

“We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Getting Alzheimer's drug Leqembi to patients can be a challenge

WSS

Why did Pfizer dish out millions for a Super Bowl ad?

Medicare Advantage proposed rates disappoint insurers

Orangutan used medicinal plant to treat wound, first time ever seen

UnitedHealth financials solid despite Change Healthcare cyberattack

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

explore

Wikipedia

knowledge

Peter Hotez and the public health issue of online harassment

Why did Pfizer dish out millions for a Super Bowl ad?

Activists slam private health insurers over coverage restrictions

Vaccine advisory panel ACIP left half staffed by HHS

Medicare details structure of new drug price negotiation program

Diversity in clinical trials starts with building trust, experts say

Alkermes shareholders re

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

What does generative AI mean for health care? We asked experts

FTC falls short on scrutinizing hospital mergers, study says

knowledge

KalVista pill reduced swelling 'attacks' caused by genetic disease

Getting Alzheimer's drug Leqembi to patients can be a challenge

Biogen Alzheimer’s drug launch off to slow start

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

What we’ve learned from the Aduhelm mess

PhRMA lawsuit over Medicare drug price negotiation tossed

leisure time

hotspot

entertainment

focus